City

Bethesda (1)

Singapore (1)

Condition

Adenocarcinomas (2)

Breast Cancer (1)

Breast Neoplasms (1)

Metastatic Solid Tumors Characterized by HER2/Neu Expression (1)

Recurrent Gynecological (1)

Overall Status

Completed (1)

Recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

National Cancer Institute (NCI) (1)

National University Hospital, Singapore (1)

Collaborator

Intervention

adenoviral transduced autologous human epidermal growth factor receptor (adher)2/neu dendritic cell (dc) vaccine (1)

pembrolizumab and lenvatinib (1)

Study Documents

Intervention Type

biological (1)

drug (1)

Funder Type

NIH (1)

Other (1)

Study Type

Interventional (2)

adenocarcinomas

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Breast Tumors, Breast Cancer, Adenocarcinomas Trial run by the NCI (AdHER2/neu DC Vaccine)

Completed

Has Results

Breast Neoplasms
+3 more

Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine

Bethesda, Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pi

Aug 12, 2022

Adenocarcinomas, Recurrent Gynecological Trial in Singapore (pembrolizumab and lenvatinib)

Recruiting

Adenocarcinomas
Recurrent Gynecological

pembrolizumab and lenvatinib

Singapore, Singapore

National University Hospital

Oct 13, 2021